MedTrace Logo

Efficacy and Safety of Imotun Capsule in Osteoarthritis of the Knee

NCT01756937 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 287

Last updated 2017-03-27

No results posted yet for this study

Summary

Efficacy and safety of Imotun capsule in osteoarthritis of the knee

Conditions

  • Osteoarthritis of the Knee

Interventions

DRUG

Imotun

300.03mg/cap,orally, 1 capsule once daily for 24 weeks

DRUG

Placebo

1 capsule once daily for 24 weeks

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Dae Hyun Yoo · Hanyang University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2016-10-31
Completion
2017-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01756937 on ClinicalTrials.gov